氨氯地平联合阿托伐他汀钙对高血压合并冠心病患者血压、血脂、心功能、血管内皮功能及炎症因子水平的影响

doi:10.3969/j.issn.1671-7171.2025.09.019

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1239 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 This study aimed to assess the therapeutic efficacy of combining amlodipine with atorvastatin calcium in patients with concurrent hypertension and coronary heart disease(CHD).【Methods】 A total of 300 patients with coexisting hypertension and CHD, treated at our hospital from January 2022 to December 2024, were selected. They were randomly assigned into two groups of 150 patients each. The control group received standard treatment with amlodipine and fluvastatin sodium, whereas the intervention group was treated with amlodipine in combination with atorvastatin calcium. Key clinical indicators, including blood pressure [systolic blood pressure(SBP), diastolic blood pressure(DBP)], lipid profiles [total cholesterol(TC), triglycerides(TG), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C)], cardiac function [cardiac index(CI), cardiac output(CO), left ventricular ejection fraction(LVEF)], endothelial function [nitric oxide(NO), endothelin-1(ET-1)], and inflammatory markers [C-reactive protein(CRP), homocysteine(Hcy)], were compared between the two groups.【Results】 After treatment, SBP and DBP in both groups were lower than before treatment, with statistically significant differences(P<0.05). And the intervention group showed significantly lower systolic and diastolic blood pressure levels compared to the control group(P<0.05). Serum TC, TG, and LDL-C levels in both groups were lower than before treatment, while the intervention group demonstrated lower levels of TC, TG, and LDL-C, and higher levels of HDL-C(P<0.05) compare to the control group. After treatment, LVEF, CI, and CO levels in both groups were higher than before treatment, with the observation group having a higher level than the control group(P<0.05). After treatment, serum NO levels in both groups were higher than before treatment, with the observation group having a higher level than the control group. Serum ET-1 levels and IMT were lower than before treatment, with the observation group having a lower level than the control group(P<0.05). Serum CRP and Hcy levels in both groups were lower than before treatment, with the observation group having a lower level than the control group(P<0.05).【Conclusion】 The combined use of amlodipine and atorvastatin calcium offers superior benefits in managing both hypertension and lipid levels, while also improving cardiac and endothelial function and attenuating systemic inflammation. This regimen presents a promising approach in the clinical management of patients with coexisting hypertension and CHD.

Key words： Hypertension Coronary Disease Amlodipine Atorvastatin Blood Pressure Endothelium, Vascular Chemokines

Received: 28 May 2025

PACS:

R544.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Bingzhen
	LIU Qingnan
	DUAN Chuanlei

Cite this article:

ZHOU Bingzhen,LIU Qingnan,DUAN Chuanlei. The Therapeutic Effects of Amlodipine Combined with Atorvastatin Calcium in Managing Hypertension Concurrent with Coronary Heart Disease[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(9): 1555-1558.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.09.019 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I9/1555

[1] 马敏,魏龙,颜秉翔. 高血压合并冠心病患者血清同型半胱氨酸、C反应蛋白、总胆红素水平及与颈动脉损害程度、冠状动脉病变程度的关系[J].海军医学杂志,2024,45(1):21-25.
[2] 吴祥娜,金莉雅,梁平平,等. 氨氯地平阿托伐他汀联合循证-情志干预模式对老年高血压合并冠心病患者的应用价值[J].中国药师,2024,27(6):1048-1054.
[3] 黄兴建,许娜,陈军. 自拟降压祛脂方联合氨氯地平阿托伐他汀钙片治疗高血压合并高血脂的临床疗效[J].心血管病防治知识,2024,14(23):45-48.
[4] 穆万丹,黄丹,何渝. 氨氯地平阿托伐他汀钙片治疗高血压合并冠心病患者血压水平及心功能的影响[J].中国医院药学杂志,2021,41(6):641-644.
[5] 中国高血压防治指南修订委员会,高血压联盟(中国),中国医疗保健国际交流促进会高血压分会,等. 中国高血压防治指南(2024年修订版)[J].中华高血压杂志, 2024,32(7):603-700.
[6] 中华医学会心血管病学分会介入心脏病学组, 中华医学会心血管病学分会动脉粥样硬化与冠心病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 等. 稳定性冠心病诊断与治疗指南[J].中华心血管病杂志, 2018, 46(9):680-694.
[7] 林霖, 高国鹏, 张雅娟. 阿托伐他汀联合氨氯地平治疗高血压合并冠心病患者的效果[J].中国医药指南, 2024, 22(34):73-75.
[8] 黄海芬,陈清勇,何芳,等. 高血压伴冠心病患者无创心输出量测量下个体化方案治疗的效果及机制[J].实用临床医药杂志,2025,29(5):70-75.
[9] 宋志超,李菊英,罗淋. 美托洛尔联合左旋氨氯地平对高血压伴冠心病患者的疗效[J].中国药物应用与监测,2025,22(2):206-210.
[10] 杨翠,钱倩倩,代雪飞. 药物重整对冠心病合并高血压患者的管理效果评价[J].实用药物与临床,2025,28(3):211-215.
[11] 王苑,王广东,吴茂林,等. 抗阻运动康复训练联合增强型体外反搏对高血压冠心病PCI术后血流动力学及心肺功能的影响[J].中国循证心血管医学杂志,2025,17(1):43-46.
[12] 王楚皓,王晶,孟伟,等. 高血压合并冠心病的客观化面象研究[J].世界中医药,2024,19(21):3234-3237.
[13] 王莉,缑芳红,王甜甜. 苯磺酸左旋氨氯地平联合阿托伐他汀钙片对高血压合并冠心病患者血压、血脂水平的影响[J].山西医药杂志,2021,50(24):3392-3395.
[14] 张可英,李秀昌.阿托伐他汀与氟伐他汀对冠心病患者心率变异性的影响[J].山东医药,2016,56(33):44-46.
[15] 陆向阳. 氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的效果分析[J].中国实用医刊,2024,51(22):95-98.